Jump to content

ANAVEX 3-71

Add links
From Wikipedia, the free encyclopedia

ANAVEX 3-71
Clinical data
Other namesANAVEX3-71; AF710B; AF-710B
Routes of
administration		Oral[1][2]
Drug classMuscarinic acetylcholine M1 receptor positive allosteric modulator; Sigma σ1 receptor agonist
Pharmacokinetic data
Elimination half-life3.56 hours[2]
M8 metabolite: 6.59 hours[2]
Identifiers
  • 1-(2,8-dimethyl-1-thia-3,8-diazaspiro[4.5]decan-3-yl)-3-(1H-indol-3-yl)propan-1-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
Chemical and physical data
FormulaC20H27N3OS
Molar mass357.52 g·mol−1
3D model (JSmol)
  • CC1N(CC2(S1)CCN(CC2)C)C(=O)CCC3=CNC4=CC=CC=C43
  • InChI=1S/C20H27N3OS/c1-15-23(14-20(25-15)9-11-22(2)12-10-20)19(24)8-7-16-13-21-18-6-4-3-5-17(16)18/h3-6,13,15,21H,7-12,14H2,1-2H3
  • Key:XWMHYQATSBWUNT-UHFFFAOYSA-N

ANAVEX 3-71, also known as AF710B, is a muscarinic acetylcholine M1 receptor positive allosteric modulator and sigma σ1 receptor agonist which is under development for the treatment of schizophrenia, Alzheimer's disease, frontotemporal dementia, other neurodegenerative disorders, and Parkinson's disease.[1][3][4][5][2] It is taken orally.[1] The drug shows pro-cognitive-like, neuroprotective, and neurorestorative effects in preclinical research.[6][7][8][4][5] The pharmacokinetics of ANAVEX 3-71 have been studied in humans.[2] ANAVEX 3-71 is under development by Anavex Life Sciences.[1][3] As of October 2025, it is in phase 2 clinical trials for schizophrenia and phase 1 trials for Alzheimer's disease, frontotemporal dementia, and other neurodegenerative disorders, whereas no recent development has been reported for Parkinson's disease.[1][3]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 "Anavex 3-71". AdisInsight. 7 October 2025. Retrieved 7 June 2026.
  2. 1 2 3 4 5 Fadiran EO, Hammond E, Tran J, Missling CU, Ette E (January 2024). "Population-Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease". Clinical Pharmacology in Drug Development. 13 (1): 21–31. doi:10.1002/cpdd.1323. PMID 38073274.
  3. 1 2 3 "Delving into the Latest Updates on ANAVEX 3-71 with Synapse". Synapse. 7 May 2025. Retrieved 7 June 2026.
  4. 1 2 Fisher A, Bezprozvanny I, Wu L, Ryskamp DA, Bar-Ner N, Natan N, et al. (2016). "AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease". Neuro-Degenerative Diseases. 16 (1–2): 95–110. doi:10.1159/000440864. PMC 4803577. PMID 26606130.
  5. 1 2 Hall H, Iulita MF, Gubert P, Flores Aguilar L, Ducatenzeiler A, Fisher A, et al. (June 2018). "AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease". Alzheimer's & Dementia. 14 (6): 811–823. doi:10.1016/j.jalz.2017.11.009. PMID 29291374.
  6. ↑ Cuello AC, Hall H, Do Carmo S (2019). "Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease". Frontiers in Pharmacology. 10 189. doi:10.3389/fphar.2019.00189. PMC 6409318. PMID 30886583.
  7. ↑ Bogár F, Fülöp L, Penke B (February 2022). "Novel Therapeutic Target for Prevention of Neurodegenerative Diseases: Modulation of Neuroinflammation with Sig-1R Ligands". Biomolecules. 12 (3): 363. doi:10.3390/biom12030363. PMC 8945408. PMID 35327555.
  8. ↑ Orciani C, Do Carmo S, Foret MK, Hall H, Bonomo Q, Lavagna A, et al. (December 2023). "Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology". Neurobiology of Aging. 132: 220–232. doi:10.1016/j.neurobiolaging.2023.09.010. PMID 37864952.
Retrieved from "https://en.wikipedia.org/w/index.php?title=ANAVEX_3-71&oldid=1358531754"